RTP Pharma Inc. Receives Broad Patent for use of a Novel Peptide in Gastrointestinal Medical Procedures
Montreal, October 28, 1997 - RTP Pharma Inc., the Canadian
operating affiliate of a private U.S. biopharmaceutical company,
has received U.S. patent 5,681,816 from the United States Patent
and Trademark Office covering a method of inducing temporary paralysis
of the gastrointestinal (GI) tract during intestinal examination.
The patent covers the use of Vasoactive Intestinal Peptide (VIP)
as a tissue relaxant to facilitate specific medical procedures
and enhance overall safety.
"The patent broadly secures the use of VIP to induce a temporary
paralysis in the GI tract where the recalcitrant problem of contractions
and spasms hinder medical procedures," said Indu Parikh,
Ph.D., the Chief Scientific Officer of RTP Pharma Inc.
Gary W. Pace, President and CEO of the Company added, "The
VIP technology, although not related to our Insoluble Drug DeliveryTM
(IDDTM) technology, represents a significant advance for a whole
class of medical procedures and speaks to the strength of our
product portfolio. In addition, we intend to conduct clinical
studies on VIP then license this product."
The U.S. patent covers the use of Vasoactive Intestinal Peptide
(VIP) prior to and during intestinal endoscopy, where the peptide
can induce needed and temporary paralysis, thereby potentially
enhancing the effectiveness and monitoring capability of this
procedure. Additionally, the patent specifies use of VIP in other
GI procedures where induced paralysis would be beneficial.
RTP Pharma Inc. is commercializing patented technology, known
as Insoluble Drug DeliveryTM (IDDTM), for the delivery of
water insoluble drugs. RTP is initially utilizing IDDTM technology
to target poorly soluble marketed drugs that would otherwise require
extensive manipulation to be therapeutically effective in injectable
and oral formulations. IDDTM technology has potential applicability
to a broad range of therapeutic classes, including anesthetics,
antifungal agents and immune suppressants. RTP Pharma has demonstrated
the viability of IDDTM technology by formulating more than 50
drugs in the laboratory. The Company currently has lead products,
including an immune suppressant and an anti-cancer agent, which
are currently undergoing Phase I/II studies.
Gary W. Pace, Ph.D.
President and CEO
RTP Pharma Inc.
Phone: (514) 362-1304
Lucy L. Morrison
Feinstein Kean Partners Inc.
Phone: (617) 577-8110